Last reviewed · How we verify
anti-CCR2 monoclonal antibody MLN1202
anti-CCR2 monoclonal antibody MLN1202 is a Small molecule drug developed by SWOG Cancer Research Network. It is currently in Phase 2 development.
At a glance
| Generic name | anti-CCR2 monoclonal antibody MLN1202 |
|---|---|
| Sponsor | SWOG Cancer Research Network |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced Melanoma (PHASE1)
- S0916, MLN1202 in Treating Patients With Bone Metastases (PHASE2)
- Efficacy and Safety of Weekly Subcutaneous MLN1202 in Improving Diabetic Nephropathy in Participants With Macroalbuminuria (PHASE2)
- Phase 1 Single Subcutaneous Dose Study of MLN1202 (PHASE1)
- Proof of Mechanism Study of MLN1202 on Atherosclerotic Inflammation in Participants With Stable Atherosclerotic Cardiovascular Disease (PHASE2)
- Study of the Safety and Efficacy of MLN1202 in Patients in Multiple Sclerosis (PHASE2)
- Double-Blind, Randomized, Placebo-Controlled Trial of MLN1202 on C-Reactive Protein Levels in Patients With Risk Factors for Cardiovascular Disease (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti-CCR2 monoclonal antibody MLN1202 CI brief — competitive landscape report
- anti-CCR2 monoclonal antibody MLN1202 updates RSS · CI watch RSS
- SWOG Cancer Research Network portfolio CI
Frequently asked questions about anti-CCR2 monoclonal antibody MLN1202
What is anti-CCR2 monoclonal antibody MLN1202?
anti-CCR2 monoclonal antibody MLN1202 is a Small molecule drug developed by SWOG Cancer Research Network.
Who makes anti-CCR2 monoclonal antibody MLN1202?
anti-CCR2 monoclonal antibody MLN1202 is developed by SWOG Cancer Research Network (see full SWOG Cancer Research Network pipeline at /company/swog-cancer-research-network).
What development phase is anti-CCR2 monoclonal antibody MLN1202 in?
anti-CCR2 monoclonal antibody MLN1202 is in Phase 2.
Related
- Manufacturer: SWOG Cancer Research Network — full pipeline